Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 4/20 | 0.65 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.42 |
| ▸ | TSHR | P16473 | 1/20 | 0.42 |
| ▸ | PPARG | P37231 | 2/20 | 0.41 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.38 |
| ▸ | SIRT2 | Q8IXJ6 | 2/20 | 0.36 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.36 |
| ▸ | PRKCA | P17252 | 3/20 | 0.36 |
| ▸ | TP53 | P04637 | 1/20 | 0.35 |
| ▸ | PKM | P14618 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2220339 | 0.98 | CYP1A2 (0.62) | CYP1A2ALDH1A1TSHRPPARGL3MBTL1 | |
| SCHEMBL14119910 | 0.98 | CYP1A2 (0.62) | CYP1A2ALDH1A1TSHRPPARGL3MBTL1 | |
| SCHEMBL3688744 | 0.94 | CYP1A2 (0.56) | CYP1A2ALDH1A1TSHRPPARGPRKCA | |
| SCHEMBL442643 | 0.85 | CYP1A2 (0.46) | CYP1A2ALDH1A1TSHRPPARGSIRT2 | |
| SCHEMBL23153408 | 0.82 | CYP1A2 (0.46) | CYP1A2ALDH1A1TSHRPPARGL3MBTL1 | |
| SCHEMBL2691445 | 0.80 | CYP1A2 (0.55) | CYP1A2ALDH1A1PPARGL3MBTL1SIRT2 | |
| SCHEMBL8710704 | 0.80 | CYP1A2 (0.71) | CYP1A2ALDH1A1TSHRPPARGL3MBTL1 | |
| SCHEMBL28238797 | 0.80 | CYP1A2 (0.71) | CYP1A2ALDH1A1TSHRPPARGL3MBTL1 | |
| SCHEMBL28237732 | 0.80 | CYP1A2 (0.71) | CYP1A2ALDH1A1TSHRPPARGL3MBTL1 | |
| SCHEMBL2861345 | 0.79 | CYP1A2 (1.00) | CYP1A2PPARGEPHX1PKM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6833458-B2 | Selective serotonin reuptake inhibitor; antidepressant, anti-Parkinson agent | DEVELOPMENT CENTER FOR BIOTECHNOLOGY (TW) | 2004-12-21 | — | — | US | claimed |
| US-20020169323-A1 | Practical syntheses of chiral trans-3, 4-disubstituted piperidines and the intermediates | DEVELOPMENT CENTER FOR BIOTECHNOLOGY (TW) | 2002-11-14 | — | — | US | claimed |
| CN-118056309-A | Flame-retardant nonaqueous electrolyte and secondary battery using same | 国立大学法人京都大学 | 2024-05-17 | — | — | CN | disclosed |
| CN-108475822-B | Nonaqueous electrolyte solution for secondary battery and secondary battery provided with same | 斯泰拉化工公司 | 2022-03-11 | — | — | CN | disclosed |
| US-7531662-B2 | Cinchona-alkaloid-based catalysts, and asymmetric alcoholysis of cyclic anhydrides using them | BRANDEIS UNIVERSITY (US) | 2009-05-12 | — | — | US | disclosed |
| EP-1638677-A4 | CATALYTIC ASYMMETRIC DESYMMETRIZATION OF PROCHIRAL AND MESO CYCLIC ANHYDRIDES | UNIV BRANDEIS (US) | 2007-10-10 | — | — | EP | disclosed |
| EP-1638677-A2 | CATALYTIC ASYMMETRIC DESYMMETRIZATION OF PROCHIRAL AND MESO CYCLIC ANHYDRIDES | Brandeis University (US) | 2006-03-29 | — | — | EP | disclosed |
| US-20050043353-A1 | Cinchona-alkaloid-based catalysts, and asymmetric alcoholysis of cyclic anhydrides using them | BRANDEIS UNIVERSITY | 2005-02-24 | — | — | US | disclosed |
| WO-2004110609-A2 | CATALYTIC ASYMMETRIC DESYMMETRIZATION OF PROCHIRAL AND MESO CYCLIC ANHYDRIDES | BRANDEIS UNIVERSITY (US) | 2004-12-23 | — | — | WO | disclosed |
| US-6833458-B2 | Selective serotonin reuptake inhibitor; antidepressant, anti-Parkinson agent | DEVELOPMENT CENTER FOR BIOTECHNOLOGY (TW) | 2004-12-21 | — | — | US | disclosed |
| US-20020169323-A1 | Practical syntheses of chiral trans-3, 4-disubstituted piperidines and the intermediates | DEVELOPMENT CENTER FOR BIOTECHNOLOGY (TW) | 2002-11-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050043353-A1 | Cinchona-alkaloid-based catalysts, and asymmetric alcoholysis of cyclic anhydrides using them | CA7, CA9, CA1 | CYP1A2 122/4885ALDH1A1 47/4885TSHR 3732/4885 |
| US-20020169323-A1 | Practical syntheses of chiral trans-3, 4-disubstituted piperidines and the intermediates | HTR4, TPH2, HTR3A | CYP1A2 98/4885ALDH1A1 1401/4885TSHR 846/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.